Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet Infect Dis. 2007 Jun;7(6):410-9.

Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?

Author information

  • 1Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Travel Medicine, Royal Free and University College Medical School, London, UK. j.zuckerman@medsch.ucl.ac.uk

Abstract

Infection with hepatitis B causes between 500,000 and 1.2 million deaths per year worldwide, and is the leading cause of liver cancer. Over 12 years ago, WHO recommended that universal childhood hepatitis B vaccination be implemented globally. Despite this, Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden, and the UK have yet to implement such a policy and instead currently adopt an "at-risk" strategy. Although all eight countries are classed as having low endemicity, factors such as increased travel and integration of immigrant communities are increasing the number of at-risk individuals in these countries. Considering the difficulty in identifying all at-risk individuals, and the lack of effectiveness of at-risk vaccination on reducing the overall incidence of hepatitis B, we recommend that these countries reassess their hepatitis B prevention strategies. Universal vaccination against hepatitis B is the only way to eliminate the major public-health impact of this disease.

Comment in

  • Universal hepatitis B vaccination. [Lancet Infect Dis. 2008]
  • Universal hepatitis B vaccination. [Lancet Infect Dis. 2008]
  • Universal hepatitis B vaccination. [Lancet Infect Dis. 2008]
PMID:
17521594
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk